| Company | GeneFrontier Corporation | ||||||||||
| Established | February 14, 2003 | ||||||||||
| Capital | 200 million yen | ||||||||||
| Additional paid in capital | 200 million yen | ||||||||||
| Board of Directors |
|
||||||||||
| Shareholders |
ITX Corporation BML, Inc. |
||||||||||
| Business |
1. Provider of Innovative Genomic Drug Discovery Research Services: ♦ Customized Human Combinatorial Monoclonal Antibody Contract Service, using Phage Display Technology partnered with Antibody by Design , a division of MorphoSys AG (Munich, Germany) ♦ Licensing of Human Immortalized Skeletal Muscle Cell Lines, partnered with Lonza. 2. Monoclonal Antibody Therapeutic Drug Discovery: ♦ Discovery of innovative Antibody Drugs partnering with various academic institutes |
||||||||||
| Head Office | Kaminari-Ichi Biru Rm#416, 2-19-17 Kaminari-mon, Taito-Ku, Tokyo 113-0034 JAPAN Phone: +81-3-5806-7801 Facsimile: +81-3-3844-6020 E-mail: info@genefrontier.com | ||||||||||
| Lab | Todai-Kashiwa Venture Plaza Rm#306 5-4-19 Kashiwa-no-Ha, Kashiwa, Chiba 277-0882 JAPAN Phone: +81-4-7137-3050 |
